Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Novartis Investigative Site, Surquillo

Novartis Investigative Site, Gosford

Novartis Investigative Site, Parkville

Novartis Investigative Site, Bern

Novartis Investigative Site, Fitzroy

Novartis Investigative Site, Prahran

Novartis Investigative Site, Liège

Novartis Investigative Site, Herston

Novartis Investigative Site, Adelaide

Novartis Investigative Site, Bruges

Novartis Investigative Site, Zurich

Novartis Investigative Site, Ghent

North Shore University Hospital North Shore Univ, Manhasset

Memorial Sloan Kettering Cancer Center Dept. of MSKCC (2), New York

Novartis Investigative Site, Toulouse

Novartis Investigative Site, Udine

Novartis Investigative Site, Montpellier

Novartis Investigative Site, Balcova / Izmir

Novartis Investigative Site, Nantes

Novartis Investigative Site, Cologne

Novartis Investigative Site, Frankfurt

University of Chicago Medical Center Dept. of U. of Chicago Hosp(3), Chicago

Nebraska Methodist Hospital Nebraska Methodist Hospital(2), Omaha

Novartis Investigative Site, Paris

University of Texas Southwestern Medical Center Dept of Simmons Cancer Center, Dallas

Novartis Investigative Site, Bobigny

Oregon Health Sciences University Dept. of OHSU (2), Portland

University of Texas/MD Anderson Cancer Center Dept of MD Anderson (14), Houston

Novartis Investigative Site, Leipzig

Novartis Investigative Site, Roma

Novartis Investigative Site, Roma

Novartis Investigative Site, Seoul

Novartis Investigative Site, Barcelona

Novartis Investigative Site, L'Hospitalet de Llobregat

Novartis Investigative Site, Ankara

Novartis Investigative Site, Aberdeen

Novartis Investigative Site, Leeds

Novartis Investigative Site, Liverpool

Novartis Investigative Site, London

Novartis Investigative Site, London